Pharmafile Logo
Pharmafocus logo
Advanced Search

Merck Serono

Showing 15 posts of 72 posts found.

Rebif image

Rebif approved for early use in MS

January 26, 2012
Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif

The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …

News

Merck Serono returns Parkinson’s drug rights to Newron

October 24, 2011
Research and Development, Sales and Marketing Merck Serono, Newron

Merck Serono has returned the rights to the Parkinson’s disease drug safinamide back to Newron. The decision comes after the …

News
Merck Serono

Merck licences new MS drug

September 19, 2011
Research and Development Cladribine, Merck KGaA, Merck Serono, PI-2301

Merck KGaA has in-licensed a new multiple sclerosis drug and aims to start it in phase II studies later this …

News
Merck Serono headquarters

Merck Serono signs neurodegenerative collaboration

June 9, 2011
Research and Development Affectis Pharmaceuticals, Merck Serono

Merck Serono has struck a deal with biotech firm Affectis Pharmaceuticals to develop oral neurodegeneration compounds. The companies will commercialise …

News
Merck Serono headquarters

Erbitux meets gold standard in rectal cancer

June 7, 2011
Research and Development, Sales and Marketing Erbitux, Merck Serono, rectal cancer

Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …

News
Merck KGaA

Merck KGaA sales soar

February 21, 2011
Sales and Marketing 2010 pharma results, Cladribine, Merck KGaA, Merck Serono, Movectro

Merck KGaA’s sales jumped last year by nearly a fifth as recent acquisitions and strong growth on core products set …

News
Blog footer

Digital Pharma: Merck Serono sets up MS social network

February 18, 2011
Medical Communications Digital Pharma blog, MS, Merck Serono, Movectro, Rebif, multiple sclerosis, social networking

Merck Serono has set up an international social network for multiple sclerosis patients, saying today’s pharma companies should go beyond …

News
Merck Serono headquarters

Merck Serono halts Movectro European licence application

February 18, 2011
Medical Communications, Sales and Marketing Cladribine, MS, Merck KGaA, Merck Serono, Movectro, fingolimod, gilenya, multiple sclerosis

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …

News
Merck Serono cancer disease awareness campaign

Digital Pharma: Merck Serono launches campaign for cancer carers

February 4, 2011
Medical Communications Cancer, Digital Pharma blog, Merck Serono, disease awareness campaigns, lung cancer

Merck Serono has launched an educational lung cancer website for the ‘people behind the patients’ in Europe. Unveiled to coincide …

News

Merck Serono and Domain to co-develop Parkinson’s drugs

January 18, 2011
Research and Development Domain Therapeutics, Merck KGaA, Merck Serono, PAM, Parkinson's disease, Parkinson’s disease, Positive Allosteric Modulator, mGluR4, metabotropic glutamate receptor 4

Merck Serono is to work with French biotech company Domain Therapeutics to develop a new treatment for Parkinson’s disease and …

News

Sanofi and Merck Serono to collaborate in oncology

December 17, 2010
Research and Development Cancer, MSC1936369B, Merck Serono, SAR245408, SAR245409, Sanofi, Sanofi-Aventis

Sanofi-Aventis and Merck Serono are to join forces to study three new cancer drug candidates. The collaboration will see the companies …

News

Merck KGaA appoints new head of pharma

December 17, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Elmar Schnee, Merck KGaA, Merck Serono, Stefan Oschmann, appoinment, manufacturing and production, research and development, sales and marketing

Merck KGaA has appointed Stefan Oschmann head of its pharmaceuticals division Merck Serono. He takes office on 1 January 2011 …

Appointment

Trial failure for Merck Serono’s Parkinson’s candidate

November 8, 2010
Research and Development Merck Serono, Newron Pharmaceuticals, Parkinson's disease, dopamine agonists, levodopa, safinamide

Merck Serono’s new alpha-aminoamide safinamide has failed to reach its primary endpoint in a study with Parkinson’s disease patients. Merck …

News

Merck Serono eyes ‘Nanobody’ potential in rheumatology

October 14, 2010
Research and Development Ablynx, Merck Serono

Merck Serono has expanded its research with Ablynx and will co-develop ‘Nanobodies’ from the Belgian biotech against an inflammatory disease …

News

Merck will appeal EMA’s Movectro decision

October 12, 2010
Sales and Marketing CHMP, EMA, Merck KGaA, Merck Serono, Movectro

Merck KGaA is poised to appeal the EMA’s decision on its MS treatment Movectro after the regulator rejected the drug …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026